MODERN METHODS OF TREATMENT OF ACTINIC KERATOSIS (LITERATURE REVIEW)

About the author:	Severhina Yu.V.	
Heading	VIEW OF THE PROBLEM	
Type of article	Scientific Article	
Annotation	The subject of the work is to study modern methods of treatment of actinic keratosis 
(AK) and compare their effectiveness.
Materials and methods. 34 international studies on the treatment of AK after 2018 
were analyzed. The inclusion criteria for the review were studies with proven efficacy
 in the treatment of AK. Exclusion criteria were review articles with proven
 effectiveness of treatment methods.
Results and discussions. Due to the increase in cases of AK and its neoplastic 
transformation (PCC), this problem remains relevant and requires increased 
monitoring of modern treatment methods. There are several treatment options for AK,
 both alone and in combination. The main therapeutic tasks in the management of
 patients with AK include the elimination of clinical and subclinical manifestations of
 the disease, prevention of  transformation into PCC, and reduction of the number of
 relapses. Both hardware (surgical, cryosurgical, laser, photodynamic (PDT)) and 
applied (5-FU, imiquimod, diclofenac, tirbanibulin) treatment methods have been 
proven effective.
Conclusions. AK is a fairly common precancerous skin disease, which increases the 
urgency of the problem in the development of effective treatment methods. Based on
 the conducted scientific screening, it was concluded that there are various methods 
of treating AK, with different percentages of positive dynamics and absence of 
relapses. Combined methods of treatment, which included the hardware method of
 treatment with the subsequent use of application methods, showed the greatest 
effectiveness.	
Tags	actinic keratosis, CO2 laser, imiquimod	
Bibliography	1.  Lindholm V, Salmivuori M, Hahtola S, Kerttu Mäkelä, Pitkänen S,
 Isoherranen K. Ablative Fractional Laser Enhances Artificial or Natural 
Daylight Photodynamic Therapy of Actinic Field Cancerization: A Randomized 
and Investigator-initiated Half-side Comparative Study. Acta Derm Venereol.
 2023;103: adv6579.
2.  Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind 
study to assess safety and efficacy of imiquimod 5% cream applied once daily 
3 days per week in one or two courses of treatment of actinic keratoses on 
the head. Br J Dermatol. 2007;157(1):133–141.
3.  Lerche CM, Heerfordt IM, Heydenreich J, Wulf HC. Alternatives to Outdoor 
Daylight Illumination for Photodynamic Therapy-Use of Greenhouses and 
Artificial Light Sources. Int J Mol Sci. 2016;17(3):309.
4.  Dréno B, Cerio R, Dirschka T, et al. A Novel Actinic Keratosis Field 
Assessment Scale for Grading Actinic Keratosis Disease Severity. Acta Derm 
Venereol. 2017;97(9):1108–1113..
5.  O’Mahoney P, Haigh N, Wood K, Brown CTA, Ibbotson S, Eadie E. A 
novel light source with tuneable uniformity of light distribution for artificial 
daylight photodynamic therapy. Photodiagnosis Photodyn Ther. 2018;23:144–150.
6.  Simon JC, Dominicus R, Karl L, Rodríguez R, Willers C, Dirschka T. A 
prospective randomized exploratory study comparing the efficacy of once-daily 
topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. J Eur Acad Dermatol Venereol. 
2015;29(5):881–889.
7.  Sinclair R, Baker C, Spelman L, Supranowicz M, MacMahon B. A review 
of actinic keratosis, skin field cancerisation and the efficacy of topical therapies.
 Australas J Dermatol. 2021;62(2):119–123.
8.  Maire C, Vignion-Dewalle AS, Cartier H, Mordon S. Artificial white light 
photodynamic therapy for actinic keratosis: a study of 38 patients in private 
office practice. J Eur Acad Dermatol Venereol. 2020;34(4): e165-e167.
9.  Steeb T, Wessely A, Harlaß M, et al. A Systematic Review and 
Meta-Analysis of Interventions for Actinic Keratosis from Post-Marketing 
Surveillance Trials. J Clin Med. 2020;9(7):2253.
10.  Bubna AK. Imiquimod –  Its role in the treatment of cutaneous 
malignancies. Indian J Pharmacol. 2015;47(4):354–359.
11.  Clebak KT, Mendez-Miller M, Croad J. Cutaneous Cryosurgery for 
Common Skin Conditions. Am Fam Physician. 2020;101(7):399–406.
12.  Piaserico S, Mazzetto R, Sartor E, Bortoletti C. Combination-Based 
Strategies for the Treatment of Actinic Keratoses with Photodynamic Therapy: 
An Evidence-Based Review. Pharmaceutics. 2022;14(8):1726.
13.  Fleming P, Zhou S, Bobotsis R, Lynde C. Comparison of the Treatment 
Guidelines for Actinic Keratosis: A Critical Appraisal and Review. J Cutan Med 
Surg. 2017;21(5):408–417.
14.  Hanke CW, Swanson N, Bruce S, Berman B, Kulp J, Levy S. Complete 
clearance is sustained for at least 12 months after treatment of actinic 
keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% 
or 2.5% cream. J Drugs Dermatol. 2011;10(2):165–170.
15.  Nisticß S, Del Duca E, Torchia V, Gliozzi M, Bottoni U, Muscoli C. 
Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% 
imiquimod in the treatment of actinic keratosis. Int J Immunopathol Pharmacol. 2018;32:2058738418757925.
16.  Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic 
keratoses: an update and comparison. Dermatol Surg. 2000;26(8):728–732.
17.  Heppt MV, Steeb T, Ruzicka T, Berking C. Cryosurgery combined with 
topical interventions for actinic keratosis: a systematic review and meta-analysis.
 Br J Dermatol. 2019;180(4):740–748
18.  Arisi M, Guasco Pisani E, Calzavara-Pinton P, Zane C. Cryotherapy for
 Actinic Keratosis: Basic Principles and Literature Review. Clin Cosmet Investig 
Dermatol. 2022;15:357–365.
19.  Zane C, Facchinetti E, Rossi MT, Specchia C, Ortel B, 
Calzavara-Pinton P. Cryotherapy is preferable to ablative CO2 laser for the 
treatment of isolated actinic keratoses of the face and scalp: a randomized 
clinical trial. Br J Dermatol. 2014;170(5):1114–1121.
20.  Dao DD, Sahni VN, Sahni DR, Balogh EA, Grada A, Feldman SR. 1% 
Tirbanibulin Ointment for the Treatment of Actinic Keratoses. Ann 
Pharmacother. 2022;56(4):494–500.
21.  Rubel DM, Spelman L, Murrell DF, et al. Daylight photodynamic therapy 
with methyl aminolevulinate cream as a convenient, similarly effective, nearly 
painless alternative to conventional photodynamic therapy in actinic keratosis
treatment: a randomized controlled trial. Br J Dermatol. 2014;171(5):1164–1171.
22.  de Berker D, McGregor JM, Mohd Mustapa MF, Exton LS, Hughes BR. 
British Association of Dermatologists’ guidelines for the care of patients with 
actinic keratosis 2017. Br J Dermatol. 2017;176(1):20–43
23.  Dianzani C, Conforti C, Giuffrida R, et al. Current therapies for actinic 
keratosis. Int J Dermatol. 2020;59(6):677–684.
24.  Palacio A. D-OCT-assisted and histology-controlled evaluation of 1064 nm 
Nd: YAG laser therapy of basal cell carcinomas. JEADV Clinical Practice. 2022. 1–9.
25.  Dohil MA. Efficacy, Safety, and Tolerability of 4% 5-Fluorouracil Cream in 
a Novel Patented Aqueous Cream Containing Peanut Oil Once Daily
 Compared With 5% 5-Fluorouracil Cream Twice Daily: Meeting the Challenge 
in the Treatment of Actinic Keratosis. J Drugs Dermatol. 2016;15(10):1218–1224.
26.  Emmerich VK, Cull D, Kelly KA, Feldman SR. Patient assessment of 
5-fluorouracil and imiquimod for the treatment of actinic keratoses: a 
retrospective study of real-world effectiveness. J Dermatolog Treat. 2022;33(4):
2075–2078.
27.  Askew DA, Mickan SM, Soyer HP, Wilkinson D. Effectiveness of 
5-fluorouracil treatment for actinic keratosis –  a systematic review of 
randomized controlled trials. Int J Dermatol. 2009;48(5):453–463.
28.  Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis
 with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002;70(2 
Suppl):22–29.
29.  Stockfleth E, von Kiedrowski R, Dominicus R, et al. Efficacy and Safety 
of 5-Fluorouracil 0.5%/Salicylic Acid 10% in the Field-Directed Treatment of
 Actinic Keratosis: A Phase III, Randomized, Double-Blind, Vehicle-Controlled 
Trial [published correction appears in Dermatol Ther (Heidelb). 2017 Jun;7(2):
263]. Dermatol Ther (Heidelb). 2017;7(1):81–96
30.  Ezzedine K, Painchault C, Brignone M. Use of complete clearance for 
assessing treatment efficacy for 5-fluorouracil interventions in actinic keratoses: 
how baseline lesion count can impact this outcome. J Mark Access Health 
Policy. 2020;8(1):1829884.
31.  Eisen DB, Asgari MM, Bennett DD, et al. Guidelines of care for the 
management of actinic keratosis. J Am Acad Dermatol. 2021;85(4): e209-e233.
32.  Noels EC, Hollestein LM, van Egmond S, et al. Healthcare utilization and 
management of actinic keratosis in primary and secondary care: a 
complementary database analysis. Br J Dermatol. 2019;181(3):544–553.
33.  Iglesias-Puzas A, Batalla A, Suh-Oh HJ, Flórez A. 0.5% 5-Fluorouracil/
10% Salicylic Acid for the Treatment of Distal Actinic Keratoses Under Daily 
Practice Conditions. J Drugs Dermatol. 2019;18(3):285–288.
34.  Garcia-Mouronte E, Berna-Rico E, de Nicolas-Ruanes B, Azcarraga-Llobet 
C, AlonsoMartinez de Salinas L, Bea-Ardebol S. Imiquimod as Local 
immunotherapy in the Management of Premalignant Cutaneous Conditions and 
Skin Cancer. Int J Mol Sci. 2023;24(13):10835.
35.  Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. 
Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of 
two placebo-controlled studies of daily application to the face and balding 
scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62(4):582–590.
36.  Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S. Imiquimod 
2.5% and 3.75% for the treatment of actinic keratoses: results of two 
placebo-controlled studies of daily application to the face and balding scalp 
for two 3-week cycles. J Am Acad Dermatol. 2010;62(4):573–581.
37.  Swanson N, Smith CC, Kaur M, Goldenberg G. Imiquimod 2.5% and 
3.75% for the treatment of actinic keratoses: two phase 3, multicenter, 
randomized, double-blind, placebo-controlled studies. J Drugs Dermatol. 
2014;13(2):166–169.
38.  Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic 
keratoses. Cochrane Database Syst Rev. 2012;12(12): CD004415..
39.  Peris K, Calzavara-Pinton PG, Neri L, et al. Italian expert consensus for 
the management of actinic keratosis in immunocompetent patients. J Eur Acad 
Dermatol Venereol. 2016;30(7):1077–1084
40.  Moscarella E, Di Brizzi EV, Casari A, et al. Italian expert consensus 
paper on the management of patients with actinic keratoses. Dermatol Ther. 
2020;33(6): e13992
41.  orizzo J, Dinehart S, Matheson R, et al. Vehicle-controlled, double-blind, 
randomized study of imiquimod 5% cream applied 3 days per week in one or 
two courses of treatment for actinic keratoses on the head. J Am Acad 
Dermatol. 2007;57(2):265–268.
42.  Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in 
combination with salicylic acid as a new lesion-directed option to treat topically 
actinic keratoses: histological and clinical study results. Br J Dermatol. 2011;
165(5):1101–1108.
43.  Markham A, Duggan S. Tirbanibulin: First Approval. Drugs. 2021;81(4):
509–513.
44.  Kaufmann R, Spelman L, Weightman W, et al. Multicentre intraindividual 
randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. 
cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol. 
2008;158(5):994–999.
45.  Blauvelt A, Kempers S, Lain E, et al. Phase 3 Trials of Tirbanibulin 
Ointment for Actinic Keratosis. N Engl J Med. 2021;384(6):512–520
46.  Nelson C, Rigel D, Smith S, Swanson N, Wolf J. Phase IV, open-label 
assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium 
topical gel (Solaraze). J Drugs Dermatol. 2004;3(4):401–407.
47.  Algorri  JF,  Ochoa  M,  Roldán-Varona  P,  Rodríguez-Cobo  L,  
López-Higuera  JM. Photodynamic Therapy: A Compendium of Latest Reviews. 
Cancers (Basel). 2021;13(17):4447
48.  Wiegell SR, Haedersdal M, Eriksen P, Wulf HC. Photodynamic therapy of 
actinic keratoses with 8% and 16% methyl aminolaevulinate and home-based 
daylight exposure: a doubleblinded randomized clinical trial. Br J Dermatol. 
2009;160(6):1308–1314
49.  Tschen EH, Wong DS, Pariser DM, et al. Photodynamic therapy using 
aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the 
face and scalp: phase IV multicentre clinical trial with 12-month follow up. 
Br J Dermatol. 2006;155(6):1262–1269.
50.  Balcere A, Rone Kupfere M, ßßma I, Krßmißa A. Prevalence, 
Discontinuation Rate, and Risk Factors for Severe Local Site Reactions with 
Topical Field Treatment Options for Actinic Keratosis of the Face and Scalp. 
Medicina (Kaunas). 2019;55(4):92
51.  Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 
0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week 
treatment in patients with actinic keratosis. Cutis. 2002;70(6):335–339.
52.  Jansen MHE, Kessels JPHM, Nelemans PJ, et al. Randomized Trial of 
Four Treatment Approaches for Actinic Keratosis. N Engl J Med. 2019;380(10):
935–946
53.  Briatico  G,  Brancaccio  G,  Scharf  C,  et  al.  Real-World  Experience  
With  Topical 5-Fluorouracil 4% (40 mg/g) Cream for the Treatment of Actinic 
Keratosis [published online ahead of print, 2023 Apr 1]. Dermatol Pract 
Concept. 2023;13(2): e2023151
54.  Reinehr CPH, Bakos RM. Actinic keratoses: review of clinical, dermoscopic,
 and therapeutic aspects. An Bras Dermatol. 2019;94(6):637–657.
55.  Wu Y, Tang N, Cai L, Li Q. Relative efficacy of 5-fluorouracil compared 
with other treatments among patients with actinic keratosis: A network 
meta-analysis. Dermatol Ther. 2019;32(3): e12822.
56.  Heppt MV, Leiter U, Steeb T, et al. S3 guideline for actinic keratosis and 
cutaneous squamous cell carcinoma –  short version, part 1: diagnosis,
 interventions for actinic keratoses, care structures and quality-of-care 
indicators. J Dtsch Dermatol Ges. 2020;18(3):275–294.
57.  Stockfleth E. Topical management of actinic keratosis and field 
cancerisation. G Ital Dermatol Venereol. 2009;144(4):459–462.
58.  Tan JHY, Hsu AAL. Nonsteroidal anti-inflammatory drug (NSAID) 
exacerbated respiratory disease phenotype: Topical NSAID and asthma 
control –  A possible oversight link. Respir Med. 2016;118:1–3.
59.  Taub AF, Garretson CB. A randomized, blinded, bilateral intraindividual, 
vehicle-controlled trial of the use of photodynamic therapy with 5-aminolevulinic 
acid and blue light for the treatment of actinic keratoses of the upper 
extremities. J Drugs Dermatol. 2011;10(9):1049–1056.
60.  Kempers S, DuBois J, Forman S, et al. Tirbanibulin Ointment 1% as a 
Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results. J Drugs 
Dermatol. 2020;19(11):1093–1100.
61.  Micali G, Lacarrubba F, Nasca MR, Schwartz RA. Topical 
pharmacotherapy for skin cancer: part I. Pharmacology. J Am Acad Dermatol. 
2014;70(6):965–978.
62.  Worley B, Harikumar V, Reynolds K, et al. Treatment of actinic keratosis: 
a systematic review. Arch Dermatol Res. 2023;315(5):1099–1108.
63.  Lai M, Pampena R, Cornacchia L, Pellacani G, Peris K, Longo C. 
Treatments of actinic cheilitis: A systematic review of the literature. J Am 
Acad Dermatol. 2020;83(3):876–887
64.  Berman B, Shabbir AQ, MacNeil T, Knudsen KM. Variables in Cryosurgery
 Technique Associated With Clearance of Actinic Keratosis. Dermatol Surg. 
2017;43(3):424–430.
65.  Wiegell SR, Fabricius S, Heydenreich J, et al. Weather conditions and 
daylight-mediated photodynamic therapy: protoporphyrin IX-weighted daylight 
doses measured in six geographical locations. Br J Dermatol. 2013;168(1):
186–191	
Publication of the article	«DERMATOLOGY AND VENEREOLOGY» №3(101), 2023 year, 7-12 pages,
	
DOI	10.33743/2308-1066-2023-3-7-12